ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION

被引：6

作者：

Beigel, J. H. ^{[1
]}

机构：

[1] NCI, Immunoregulat Lab, Div Intramural Res, NIAID,SAIC Frederick Inc,NIH, Frederick, MD 21702 USA

来源：

DRUGS OF THE FUTURE | 2010年 / 35卷 / 05期

基金：

美国国家卫生研究院;

关键词：

CYCLOPENTANE NEURAMINIDASE INHIBITORS; IN-VIVO ACTIVITIES; A VIRUS-INFECTION; H5N1; VIRUS; PASSIVE IMMUNOTHERAPY; CELL-CULTURE; OSELTAMIVIR; EFFICACY; COMBINATION; ZANAMIVIR;

D O I：

10.1358/dof.2010.035.05.1487081

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

The recent pandemic of H1N1 has demonstrated the potential vulnerability of the human population to novel influenza viruses. While there is recent increased interest and effort in developing effective anti-influenza agents, few new products have entered clinical studies. This review will highlight the limited armamentarium of licensed influenza agents, and discuss novel compounds and strategies that have entered clinical studies and may therefore be imminently available to the treating clinician.

引用

页码：385 / 392

页数：8

共 76 条

[1]

BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design [J].

Babu, YS ;

Chand, P ;

Bantia, S ;

Kotian, P ;

Dehghani, A ;

El-Kattan, Y ;

Lin, TH ;

Hutchison, TL ;

Elliott, AJ ;

Parker, CD ;

Ananth, SL ;

Horn, LL ;

Laver, GW ;

Montgomery, JA .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (19) :3482-3486

[2]

Barnard Dale L., 2006, Antiviral Chemistry & Chemotherapy, V17, P275

[3]

BARON S, 2003, INT C ANT RES

[4]

BEREZINA A I, 1956, Sov Med, V20, P67

[5]

BILDA I, 1963, Kinderarztl Prax, V31, P341

[6]

The Emergency Use Authorization of Peramivir for Treatment of 2009 H1N1 Influenza [J].

Birnkrant, Debra ;

Cox, Edward .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (23) :2204-2207

[7]

Borroso L, 2005, ANTIVIR THER, V10, P901

[8]

Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers [J].

Cass, LMR ;

Efthymiopoulos, C ;

Bye, A .

CLINICAL PHARMACOKINETICS, 1999, 36 (Suppl 1) :1-11

[9]

Centers for Disease Control and Prevention (CDC), 2006, MMWR Morb Mortal Wkly Rep, V55, P44

[10]

Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P433

← 1 2 3 4 5 6 7 8 →